938 related articles for article (PubMed ID: 33444529)
21. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
[TBL] [Abstract][Full Text] [Related]
22. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
23. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
Mutter RW; Giri S; Fruth BF; Remmes NB; Boughey JC; Harless CA; Ruddy KJ; McGee LA; Afzal A; Gao RW; Shumway DA; Vern-Gross TZ; Villarraga HR; Kenison SL; Kang Y; Wong WW; Stish BJ; Merrell KW; Yan ES; Park SS; Corbin KS; Vargas CE
Lancet Oncol; 2023 Oct; 24(10):1083-1093. PubMed ID: 37696281
[TBL] [Abstract][Full Text] [Related]
24. Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial.
Sun S; Jonsson H; Salén KG; Andén M; Beckman L; Fransson P
Eur J Health Econ; 2023 Mar; 24(2):237-246. PubMed ID: 35587847
[TBL] [Abstract][Full Text] [Related]
25. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
28. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
[TBL] [Abstract][Full Text] [Related]
30. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
[TBL] [Abstract][Full Text] [Related]
31. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
32. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
33. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
[TBL] [Abstract][Full Text] [Related]
35. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA
J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637
[TBL] [Abstract][Full Text] [Related]
36. Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.
Jereczek-Fossa BA; Surgo A; Maisonneuve P; Maucieri A; Gerardi MA; Zerini D; Marvaso G; Ciardo D; Volpe S; Rojas DP; Riva G; Alessandro O; Dicuonzo S; Fanetti G; Romanelli P; Starzyńska A; Cattani F; Cambria R; Fodor C; Garibaldi C; Romanò C; De Cobelli O; Orecchia R
Radiol Med; 2019 Jan; 124(1):65-78. PubMed ID: 30219945
[TBL] [Abstract][Full Text] [Related]
37. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial.
Mendez LC; Crook J; Martell K; Schaly B; Hoover DA; Dhar A; Velker V; Ahmad B; Lock M; Halperin R; Warner A; Bauman GS; D'Souza DP
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):803-812. PubMed ID: 38072323
[TBL] [Abstract][Full Text] [Related]
38. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Jovic G; Syndikus I; Khoo V; Cowan RA; Graham JD; Aird EG; Bottomley D; Huddart RA; Jose CC; Matthews JH; Millar JL; Murphy C; Russell JM; Scrase CD; Parmar MK; Sydes MR
Lancet Oncol; 2014 Apr; 15(4):464-73. PubMed ID: 24581940
[TBL] [Abstract][Full Text] [Related]
39. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]